🚨 Major breakthrough in obesity pharmacotherapy!

The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉

🌍 Global, double-blind RCTs

⚖️ >90% lost ≥5% body weight

🩺 SBP ↓, QoL ↑, prediabetes reversed in 88%

⚠️ GI side effects common but mostly mild

💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.

#Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine